This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (20)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Ophthalmology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Todd L. Maus, MD; Cherie Nau; Richard F. Brubaker, MD

Arch Ophthalmol. 1999;117:586-591.

Objective  To compare the mechanism of action of short-term administration of brimonidine tartrate and apraclonidine hydrochloride as topical ocular hypotensive agents.

Subjects and Methods  Two randomized, double-masked, placebo-controlled studies of 19 normal human subjects were carried out. The first study compared brimonidine with apraclonidine in timolol maleate–treated eyes, and the second study compared latanoprost with placebo in timolol-treated eyes. The rate of aqueous flow and intraocular pressure were measured in both studies. The topical drug combinations were instilled the night before and repeated the morning before the measurements. Aqueous humor flow was measured by the rate of disappearance of topically applied fluorescein. Intraocular pressure was measured by pneumatonometry every 2 hours from 8:15 AM to 4:15 PM.

Results  Both brimonidine and apraclonidine further reduced aqueous flow in timolol-treated eyes from 1.23±0.21 µL/min to 0.96±0.16 µL/min and 0.98±0.17 µL/min, respectively. Consistent reductions were observed in intraocular pressure, with average reductions of 19% with brimonidine and 17% with apraclonidine. Latanoprost had no effect on aqueous flow in timolol-treated eyes (P=.15), but showed an average reduction in intraocular pressure of 13%.

Conclusions  Brimonidine and apraclonidine are similar in their effects on the aqueous system. Both reduce intraocular pressure in the timolol-treated eye, primarily, if not exclusively, by further suppressing aqueous flow. In contrast, latanoprost reduces intraocular pressure in the timolol-treated eye without affecting aqueous flow.

From the Department of Ophthalmology, Mayo Clinic and Mayo Foundation, Rochester, Minn.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Assessment of Ocular Hypotensive Mechanisms and Additivity of Antiglaucoma Drugs in Humans
Paul F. Kaufman
Arch Ophthalmol. 1999;117(5):673-674.
EXTRACT | FULL TEXT  

Archives of Ophthalmology Reader's Choice: Continuing Medical Education
Arch Ophthalmol. 1999;117(5):707-708.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Analysis of {alpha}2-adrenergic Receptors and Effect of Brimonidine on Matrix Metalloproteinases and Their Inhibitors in Human Ciliary Body
Ooi et al.
IOVS 2009;50:4237-4243.
ABSTRACT | FULL TEXT  

Effects of Topical Clonidine versus Brimonidine on Choroidal Blood Flow and Intraocular Pressure during Squatting
Weigert et al.
IOVS 2007;48:4220-4225.
ABSTRACT | FULL TEXT  

Aqueous Humor Flow in Normal Human Eyes Treated With Brimonidine and Dorzolamide, Alone and in Combination
Tsukamoto and Larsson
Arch Ophthalmol 2004;122:190-193.
ABSTRACT | FULL TEXT  

Potent {alpha}2A-Adrenoceptor-Mediated Vasoconstriction by Brimonidine in Porcine Ciliary Arteries
Wikberg-Matsson and Simonsen
IOVS 2001;42:2049-2055.
ABSTRACT | FULL TEXT  

Aqueous Humor Flow in Normal Human Eyes Treated With Brimonidine and Timolol, Alone and in Combination
Larsson
Arch Ophthalmol 2001;119:492-495.
ABSTRACT | FULL TEXT  

Ocular Effects of Apraclonidine in Horner Syndrome
Morales et al.
Arch Ophthalmol 2000;118:951-954.
ABSTRACT | FULL TEXT  

Assessment of Ocular Hypotensive Mechanisms and Additivity of Antiglaucoma Drugs in Humans
Kaufman
Arch Ophthalmol 1999;117:673-674.
FULL TEXT